olivLaw · US equity research
BioLife Solutions, Inc. BLFS
Electromedical & Electrotherapeutic Apparatus · SIC 3845 · Vertical: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
BioLife Solutions develops, manufactures and sells bioproduction products, mainly biopreservation media, for cell and gene therapies, a growing segment. In the second quarter of 2026 revenue reached 28.5 million USD, and the company agreed to be acquired by Repligen, a deal that could close in the fourth quarter of 2026.
At the close of 07 Oct 2026, BioLife Solutions, Inc. (BLFS) stock was 38.61 USD, with P/E 33.5 on diluted EPS of 1.15 USD over the last 12 months, 52-week range 38.61–38.61 USD. Latest reported quarter (Q2 2026): revenue of 28.5 m USD (+21.5% YoY), net income of 45.1 m USD, diluted EPS 0.91 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- unavailable
- Bollinger (20, 2)
- unavailable – unavailable
- SMA 50 / 200
- unavailable / unavailable
- MACD (12, 26, 9)
- unavailable / unavailable
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | unavailable | −2.0% | unavailable | — |
| 3 months | unavailable | −2.2% | unavailable | — |
| 6 months | unavailable | +4.3% | unavailable | — |
| Year to date | unavailable | +10.6% | unavailable | — |
| 1 year | unavailable | +10.5% | unavailable | −1.5% |
| 3 years | unavailable | +73.7% | unavailable | −18.0% |
| 5 years | unavailable | +61.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.4 m | 15.1 m | 22.1 m | 23.4 m | 28.1 m | 18.8 m | 27.5 m | 28.5 m |
| Cost of revenue | — | — | 7.3 m | 8.2 m | — | — | 10.0 m | 10.2 m |
| Gross profit | — | — | 14.8 m | 15.2 m | — | — | 17.5 m | 18.3 m |
| Research & development | 1.9 m | -1.2 m | 1.4 m | 2.0 m | 2.7 m | -67.0 k | 2.7 m | 3.0 m |
| Operating income | -418.0 k | 542.0 k | -499.0 k | -16.1 m | -89.0 k | 1.3 m | 27.0 k | 1.7 m |
| Depreciation & amortisation | 1.4 m ≈ | 937.0 k | 682.0 k | 674.0 k ≈ | 636.0 k ≈ | 261.0 k | 374.0 k | 411.0 k ≈ |
| Pre-tax income | -551.0 k | 469.0 k | 285.0 k | -15.2 m | 703.0 k | 3.4 m | 1.2 m | 2.8 m |
| Income tax | -80.0 k | 24.0 k | 14.0 k | 126.0 k | 82.0 k | -173.0 k | 62.0 k | -42.4 m |
| Net income | -1.7 m | 12.5 m | -448.0 k | -15.8 m | 621.0 k | 11.1 m | 1.2 m | 45.1 m |
| Diluted EPS | -0.04 | 0.27 ≈ | 0.00 | -0.33 | 0.01 | 0.21 ≈ | 0.02 | 0.91 |
| Operating cash flow | 4.8 m ≈ | 1.6 m | 1.7 m | 7.4 m ≈ | 6.1 m ≈ | 4.9 m | -491.0 k | 6.3 m ≈ |
| Capex | — | — | 175.0 k | 1.7 m ≈ | — | — | 167.0 k | 1.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | ⚠ 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.7 m | 27.4 m | 48.1 m | 119.2 m | 76.2 m | 68.0 m | 74.6 m | 96.2 m |
| Revenue YoY | +79.1% | +38.6% | +75.7% | +147.8% | — | −10.8% | +9.7% | +28.9% |
| Net income | -25.0 m | -1.7 m | 2.0 m | -8.9 m | -139.8 m | -68.0 m | -20.2 m | -4.6 m |
| Net income YoY | unavailable | unavailable | unavailable | −549.2% | — | unavailable | unavailable | unavailable |
| Diluted EPS | -1.56 | -0.09 | -0.06 | -0.23 | -3.25 | -1.55 | -0.44 | -0.10 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | — | unavailable | unavailable | unavailable |
| net % | -126.7% | -6.1% | 4.1% | -7.5% | -183.4% | -100.0% | -27.0% | -4.8% |
| Free cash flow | 1.8 m | 538.0 k | 4.7 m | -13.0 m | -18.9 m | -18.9 m | 5.2 m | 10.6 m |
The series breaks before 2022: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 33.0 m USD
- Financial debt
- 5.0 m USD
- Net debt
- -28.0 m USD
- Equity
- 371.9 m USD
- Total assets
- 405.9 m USD
- Debt / equity
- 0.01x
- Current ratio
- 5.94x
- ROE
- -1.3%
- ROA
- -1.1%
- FCF margin
- 11.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 48.1 m | 119.2 m | 76.2 m | 68.0 m | 74.6 m | 96.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | — | — | — | 26.7 m | 24.6 m | 34.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Gross profit | — | — | — | 41.3 m | 50.1 m | 62.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Research & development | 6.7 m | 11.8 m | 8.7 m | 5.5 m | 4.8 m | 7.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -6.2 m | -35.2 m | -5.9 m | -17.2 m | -4.5 m | -16.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 2.0 m | 4.7 m | 6.8 m | 7.1 m | 5.2 m | 2.3 m | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | -4.2 m ≈ | -30.5 m ≈ | 852.0 k ≈ | -10.1 m ≈ | 683.0 k ≈ | -14.3 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Pre-tax income | -1.3 m | -29.0 m | -4.8 m | -12.2 m | -8.8 m | -12.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | -3.3 m | -20.1 m | -5.2 m | -64.0 k | -38.0 k | 49.0 k | SEC (XBRL)· 26 Feb 2026verified |
| Net income | 2.0 m | -8.9 m | -139.8 m | -68.0 m | -20.2 m | -4.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | -0.06 | -0.23 | -3.25 | -1.55 | -0.44 | -0.10 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | — | 38.5 m | 43.1 m | 43.7 m | 46.1 m | 48.6 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 90.4 m | 69.9 m | 19.4 m | 27.9 m | 91.5 m | 33.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 8.0 m | 23.2 m | 33.9 m | 7.9 m | 8.5 m | 8.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Inventories | 11.6 m | 28.3 m | 34.9 m | 27.2 m | 29.0 m | 30.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 114.7 m | 126.1 m | 138.5 m | 120.6 m | 148.8 m | 136.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 10.1 m | 17.7 m | 23.6 m | 5.7 m | 6.0 m | 14.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Goodwill | 58.4 m | 58.4 m | 224.7 m | 212.3 m | 208.6 m | 208.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Intangibles (excl. goodwill) | 31.0 m | 152.1 m | 32.1 m | 12.0 m | 5.6 m | 4.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 234.8 m | 554.3 m | 450.2 m | 412.7 m | 399.5 m | 405.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 3.7 m | 14.9 m | 15.4 m | 2.3 m | 3.4 m | 1.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Short-term debt | 614.0 k | 862.0 k | 1.8 m | 6.3 m | 10.9 m | 5.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Long-term debt | 655.0 k | 6.4 m | 23.8 m | 17.6 m | 5.0 m | 0 | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 15.6 m | 42.7 m | 44.6 m | 42.2 m | 32.7 m | 23.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 29.6 m | 76.2 m | 86.0 m | 75.1 m | 50.6 m | 34.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 204.4 m † | 478.0 m † | 364.2 m † | 337.7 m † | 348.9 m † | 371.9 m † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 6.6 m | -4.6 m | -8.5 m | -12.5 m | 8.4 m | 20.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 2.0 m | 8.4 m | 10.4 m | 6.4 m | 3.2 m | 9.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | 4.7 m ≈ | -13.0 m ≈ | -18.9 m ≈ | -18.9 m ≈ | 5.2 m ≈ | 10.6 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -24.7 m | -13.2 m | -58.1 m | 17.8 m | 58.3 m | -71.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 102.1 m | -2.8 m | 16.3 m | 10.6 m | -6.8 m | -10.9 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 45.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
07 Oct 2026Source: olivLaw, closing series
Market cap: unavailable
The price is older than the freshness threshold; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
46% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 1.94 – 28.07 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDA1.94 – 2.23 (Mid 2.15)3 companies used · median multiple 17.4x · quartiles 15.2x – 18.2xITGR, MDT, TMDX
- Peers: P/E24.87 – 28.07 (Mid 25.14)5 companies used · median multiple 21.8x · quartiles 21.5x – 24.3xCNMD, ELMD, LIVN, MDT, TMDX
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 45.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 0.7% | 50 (vs peers) | 23% |
| Net margin · Quality | 56.4% | 100 (vs peers) | 14% |
| FCF conversion · Quality | 14.0% | 0 (on a fixed band) | 14% |
| Revenue CAGR 3Y · Growth | 8.1% | 67 (on a fixed band) | 18% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | -5.1x | 100 (on a fixed band) | 23% |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 9.7x | 100 (on a fixed band) | 9% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 2/3 factors with a value
- Growth· partial67/100 · 1/2 factors with a value
- Quality50/100 · 3/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
BioLife Solutions, Inc. (BLFS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 96.2 m USD in 2025; YoY growth 28.9%; net margin 56.4%; ROE 15.1%; net debt/EBITDA -5.1x.
The estimated value range is 13.41–15.15 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 45.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 56.4%
- Net debt / EBITDA: -5.1x
- Current ratio: 9.7x
What contradicts it
- FCF conversion: 14.0%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): EPS CAGR 3Y, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Electromedical & Electrotherapeutic Apparatus (SIC 3845) · same industry (4-digit SIC) · compared with 24 companies
Multiples and returns vs the median
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| MDTMedtronic plc | 126.5 bn | 24.3 | 10.7% | 13.9% | +8.4% | −6% / +25% |
| LIVNLivaNova PLC | 5.2 bn | 27.8 | 15.4% | 12.8% | +10.7% | +48% / +110% |
| ITGRInteger Holdings Corporation | 4.3 bn | 42.5 | 6.0% | 5.7% | +8.0% | +75% / +45% |
| AXGNAxogen, Inc. | 3.1 bn | — | -10.3% | -12.0% | +20.2% | +79% / +684% |
| TMDXTransMedics Group, Inc. | 2.5 bn | 18.9 | 36.3% | 22.7% | +37.1% | −50% / −4% |
| BLFSBioLife Solutions, Inc. | 1.9 bn | 33.5 | 15.1% | 56.4% | +28.9% | unavailable / unavailable |
| CNMDConmed Corporation | 1.6 bn | 21.8 | 7.1% | 5.4% | +5.2% | +24% / −50% |
| CBLLCeriBell, Inc. | 1.1 bn | — | -52.5% | -68.0% | +36.1% | +61% / unavailable |
| INMDInMode Ltd. | 899.7 m | 9.9 | 13.5% | 25.3% | −6.2% | −0% / −40% |
| CVCapsoVision, Inc | 342.8 m | — | — | -214.7% | +15.3% | +23% / unavailable |
| ELMDElectromed, Inc. | 234.3 m | 21.5 | 23.3% | 15.3% | +15.3% | +5% / +172% |
| FOCLEdap Tms SA | 162.9 m | — | -321.7% | -49.1% | +1.6% | +81% / −17% |
| VANIVivani Medical, Inc. | 96.5 m | — | -220.4% | — | unavailable | −21% / +13% |
| STXSStereotaxis, Inc. | 95.9 m | — | -325.9% | -74.2% | +20.3% | −61% / −42% |
| NRXSNeuraxis, Inc. | 86.1 m | — | -139.8% | -144.4% | +32.9% | +147% / +117% |
| OMOutset Medical, Inc. | 83.5 m | — | -59.2% | -63.1% | +5.1% | −3% / −94% |
| ECORelectroCore, Inc. | 75.7 m | — | — | -40.0% | +27.2% | +66% / +49% |
| POCIPrecision Optics Corporation, Inc. | 53.1 m | — | -22.3% | -11.5% | +65.2% | +3% / −18% |
| NXLNexalin Technology, Inc. | 34.4 m | — | -240.3% | -4,139.4% | +78.8% | −95% / −87% |
| QTIQt Imaging Holdings, Inc. | 32.1 m | — | -2,125.0% | -77.3% | +287.9% | −64% / −99% |
| NUWENuwellis, Inc. | 19.2 m | — | — | -125.6% | −5.4% | −94% / −100% |
| IRIXIridex Corp | 12.6 m | — | -73.1% | -6.9% | unavailable | −26% / −72% |
| NDRAEndra Life Sciences Inc. | 7.4 m | — | -152.0% | — | unavailable | −16% / −100% |
| ITOCiTonic Holdings Ltd | — | — | -82.8% | -974.7% | +16.7% | −80% / unavailable |
| HYPRHyperfine, Inc. | 0 | — | -97.0% | -210.8% | +5.2% | −30% / −41% |
1- and 3-year price returns: for BLFS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
BioLife Solutions develops, manufactures and sells bioproduction products, mainly biopreservation media, for cell and gene therapies, a growing segment. In the second quarter of 2026 revenue reached 28.5 million USD, and the company agreed to be acquired by Repligen, a deal that could close in the fourth quarter of 2026 123.
SWOT
Strengths
- Leading position in biopreservation media for cell and gene therapies, with a high share of US commercial clinical trials 3.
- High gross margin and rising revenue in the first half of 2026, with adjusted EBITDA above a quarter of revenue in the second quarter 3.
- Integrated product portfolio across several steps of the CGT workflow, which supports cross-selling to existing customers 1.
Weaknesses
- Heavy dependence on one main product, CryoStor, which accounts for most revenue 1.
- High customer concentration, with a small number of customers providing a significant share of revenue 1.
- Quarterly results can fluctuate significantly, and second-quarter GAAP profit was lifted by a non-recurring tax benefit 13.
Opportunities
- A growing number of approved CGT therapies could expand the customer base and use of the company's products 3.
- The PanTHERA technology could strengthen biopreservation capabilities if it reaches commercial viability 1.
- Cross-selling to existing customers could raise revenue without necessarily adding new customers 1.
Threats
- Larger competitors with greater resources could develop more effective or less costly products 1.
- Product defects or manufacturing problems could lead to lost revenue, recalls and litigation 1.
- Supply chain disruptions, especially at single-source suppliers, could affect the ability to deliver products 1.
Risks
- Completion of the Repligen acquisitionhigh
The transaction depends on shareholder and regulatory approvals; if it does not complete, the company's plans could be affected 23.
- Dependence on a single producthigh
Most revenue comes from CryoStor products, so demand or regulatory problems could have a major impact 1.
- Customer concentrationmedium
Loss of one of the large customers or changes in their orders could significantly reduce revenue 1.
- Goodwill and intangible asset impairmentmedium
The carrying value of goodwill and other intangible assets is significant and could require impairment charges if conditions worsen 1.
- Product liability and recallsmedium
Product defects could lead to claims and recall costs, and insurance might not fully cover these losses 1.
Investment thesis
What would need to be true (bull case)
- If demand for biopreservation media keeps growing, revenue could sustain the pace seen in the first half of 2026 2.
- Its leading position in clinical trials and the large number of therapies using its products could generate recurring revenue 3.
- The Repligen combination could give shareholders cash and stock consideration if the transaction completes 23.
What would break the thesis
- If the Repligen transaction does not complete, uncertainty about the company's strategy could persist 2.
- Dependence on one product and a few customers could make revenue vulnerable to changes in orders 1.
- Second-quarter 2026 GAAP profit was lifted by a non-recurring tax benefit, so it does not necessarily reflect operating performance 3.
What to watch
- Completion or failure of the Repligen transaction, including shareholder approvalQ4 2026
- Quarterly results and revenue trends for biopreservation mediaQ3 2026
- Additional approvals of CGT therapies using the company's productsnext 12 months
- Changes in customer concentration and CryoStor's share of revenuenext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company describes its business as developing, manufacturing and marketing bioproduction products and services that improve quality and reduce risk in the manufacturing, distribution and transport of biologic materials for the cell and gene therapy (CGT) industry 1. Its portfolio is one revenue line with three main offerings: cell processing, including biopreservation media and hPL media, and automated thawing devices 1. In 2025 it sold several non-core units, including SAVSU, CBS, SciSafe and Global Cooling, and acquired the remaining 90% of PanTHERA, which holds an ice recrystallization inhibitor technology 1. In July 2026 it agreed to a merger with Repligen 23.
Segments
Biopreservation media (CryoStor and HypoThermosol)
These are the company's main products and generate most of its revenue. In 2025, CryoStor products accounted for about 82% of revenue 1. The media are serum-free and protein-free and are manufactured under cGMP, and the company says they are used in several hundred active clinical trials 1.
Market context
The CGT market is expanding quickly. According to the Alliance for Regenerative Medicine as cited by the company, there were over 1,900 ongoing clinical trials at year-end 2025, and about 11.1 billion USD was invested in regenerative medicine in 2025 1. Expected revenues from recently approved CGT therapies over the next five years are about 2.0 billion USD 1. The company's revenue is geographically concentrated: 80% came from the United States in 2025 1.
Trends
- Rising demand for biopreservation mediatailwind
Revenue for the first half of 2026 rose 23%, which the company attributes mainly to customer demand for its biopreservation media 2. If this trend holds, it could support growth in the coming periods.
- Approvals of CGT productstailwind
The company expects approvals for eight additional products, geographic expansions or new indications over the next 12 months, which could increase use of its media 3.
- Customer concentrationheadwind
The company relies on a limited number of large customers: three customers generated about 29% of revenue in 2025 1. Losing one of them could significantly affect results.
- Repligen acquisition agreementmixed
The merger provides for cash and Repligen stock payments and would make BioLife a wholly owned subsidiary with no public trading 23. Completion depends on shareholder and regulatory approvals.
Competitive position
The company acknowledges it operates in a highly competitive industry where many rivals are much larger and have greater financial, technical and marketing resources 1. Competition comes from lower-cost generic or in-house formulations as well as products based on animal serum or DMSO 1.
- Repligen CorporationRGEN
Company that agreed to acquire BioLife, paying in cash and in its own shares 23.
- Generic media and in-house formulation makers
Alternatives to BioLife's proprietary media described in the annual report as cheaper but of variable quality 1.
- Makers of animal-serum or DMSO-based media
Competitors using isotonic formulations, serum or a single cryoprotectant 1.
- Large biopharma companies with in-house capabilities
Larger companies that could develop comparable or superior technologies, according to the official filings 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching CostYahoo Finance — News · 04 Sept 2026 · EN
- Biolife Is Said to Have Drawn Takeover Interest From RepligenBloomberg Markets · 26 Jun 2026 · EN
The latest news item in our archive is from 04 Sept 2026; the newest SEC filing is from 06 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report06 Oct 2026Acquisition or disposition of assets · Delisting notice · Item 3.03 · Item 5.01 · Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Current report09 Sept 2026Other events
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report03 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Current report22 Jul 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Current report03 Jun 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Current report02 Mar 2026Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / BioLife Solutions, Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / BioLife Solutions, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / BioLife Solutions, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.